Mark Jeffrey DeLong - Chief Business & Strat Officer at Apellis Pharmaceuticals, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
Chief Business & Strat Officer
Issuer Symbol
APLS on Nasdaq
All Insider Reports
All Insider Reports

Mark Jeffrey DeLong - trading volume in the past year for Apellis Pharmaceuticals, Inc.

Holdings reported by Mark Jeffrey DeLong for Apellis Pharmaceuticals, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Common Stock 78,353 $1,705,384 $21.77 22 Jan 2026 Direct
Stock Option (Right to Buy) 82,500 $1,599,675 $19.39 09 Jun 2025 Direct Common Stock

Transactions reported by Mark Jeffrey DeLong for Apellis Pharmaceuticals, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.